Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Long-Term Debt Repayments (2016 - 2021)

Pharma-Bio Serv (PBSV) has disclosed Long-Term Debt Repayments for 12 consecutive years, with $64228.0 as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Long-Term Debt Repayments rose 2244.94% year-over-year to $64228.0, compared with a TTM value of $64228.0 through Apr 2022, down 11.61%, and an annual FY2020 reading of $11030.0, down 83.7% over the prior year.
  • Long-Term Debt Repayments was $64228.0 for Q2 2021 at Pharma-Bio Serv, up from $2851.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $64228.0 in Q2 2021 and bottomed at $2631.0 in Q3 2019.
  • Average Long-Term Debt Repayments over 5 years is $11967.9, with a median of $3306.5 recorded in 2018.
  • The sharpest move saw Long-Term Debt Repayments plummeted 95.36% in 2020, then soared 2244.94% in 2021.
  • Year by year, Long-Term Debt Repayments stood at $3263.0 in 2017, then increased by 22.25% to $3989.0 in 2018, then tumbled by 33.19% to $2665.0 in 2019, then increased by 5.55% to $2813.0 in 2020, then soared by 2183.26% to $64228.0 in 2021.
  • Business Quant data shows Long-Term Debt Repayments for PBSV at $64228.0 in Q2 2021, $2851.0 in Q1 2021, and $2813.0 in Q4 2020.